Abstract
Background: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics. Methods: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (R) Turbuhaler (R))(h) maintenance and reliever therapy (Symbicort SMART (R)) at two maintenance doses of budesonide/formoterol (160/4.5 mu g), 1 x 2 and 2 x 2, in patients with asthma who were symptomatic despite treatment with ICS +/- long-acting beta(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged
| Original language | English |
|---|---|
| Pages (from-to) | 189-196 |
| Number of pages | 8 |
| Journal | Respiratory Medicine |
| Volume | 106 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2012 |
Keywords
- ACQ-5
- Asthma
- Budesonide/formoterol maintenance and reliever therapy
- Propensity-matched controls
- Smokers
- Symbicort SMART
Fingerprint
Dive into the research topics of 'Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver